Continuous Glucose Monitor
Veri leverages proven Libre CGM technology backed by dozens of RCTs/meta-analyses for accuracy (MARD 9.3%) and efficacy in stabilizing glucose, with program data showing 72% user improvement (n=739). Safety is solid per FDA clearance but tempered by device recalls and MAUDE reports of inaccuracies. Quality benefits from established sensor but lacks supplement-style purity testing. Overall, effective for metabolic insights in healthy users vs category peers.
Veri CGM Program effectively delivers accurate glucose insights via FDA-cleared Libre sensors (9.3% MARD, strong RCT evidence) and app/coaching for metabolic health in non-diabetics. User data shows 72% improvement, but watch for sensor recalls. Good option at category-average pricing.